The short answer
Transient worsening of diabetic retinopathy following rapid improvement in glycaemic control is a long-recognised phenomenon, documented across intensive-control studies decades before incretin therapies existed. It reflects the pace of change rather than any particular agent.
Key facts
- Phenomenon
- Early worsening of retinopathy
- Trigger
- Rapid glycaemic improvement
- Timing
- Transient, early in treatment
- Predates
- Every modern diabetes medicine
- Risk concentrated in
- Pre-existing retinopathy, high baseline HbA1c
- Long-term direction
- Better control remains protective
The apparent paradox
Poor glycaemic control causes retinopathy over years. Yet improving control rapidly can worsen retinopathy in the short term. Both statements are true, and reconciling them requires separating the long-run driver of disease from the short-run response to a change in conditions.
Why the retina responds to change rather than level
Retinal vessels damaged by prolonged hyperglycaemia have adapted to that environment: their blood flow regulation, permeability and metabolic handling have all adjusted. Rapidly changing the environment forces a readjustment, and a compromised vascular bed handles abrupt change poorly. It is the transition that is stressful, not the improved state.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Where the risk concentrates
In people who already have retinopathy and whose starting HbA1c is high, meaning the vessels are already damaged and the change will be large. Someone with healthy retinal vasculature and modest baseline elevation has little to worsen and a smaller change to absorb.
Why this makes effective drugs look worse
The phenomenon scales with how much and how fast HbA1c falls. A more effective glucose-lowering agent produces a larger, faster fall, and therefore encounters this more. That creates the perverse appearance that a better drug carries more risk, when what is being observed is the drug working well.
Why it does not argue against treatment
The worsening is transient and the long-term direction is unchanged. Sustained better control protects the retina. This is a sequencing issue rather than a trade-off, and it is managed through awareness and monitoring in the people whose baseline puts them at risk.
How to read a trial signal in this light
A retinopathy signal in a trial of an effective glucose-lowering agent may reflect this phenomenon rather than a property of the molecule. Distinguishing them requires asking whether the effect tracks the magnitude and speed of HbA1c reduction or the specific compound, which is the question the 2018 analysis title poses.
Frequently asked questions
Can improving glucose control worsen the eye?
Transiently, yes. Early worsening of retinopathy after rapid glycaemic improvement is long recognised and predates modern diabetes medicines.
Why does that happen?
Damaged retinal vessels have adapted to prolonged hyperglycaemia. Rapid change forces a readjustment a compromised vascular bed handles poorly.
Does it mean control should not be improved?
No. The worsening is transient and sustained better control protects the retina. It is a sequencing issue, managed by monitoring those at risk.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedVilsbøll T et al., Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018 (PMID 29178519)pubmed.ncbi.nlm.nih.gov
- PubMedVujosevic S et al. Acta Diabetol 2025 (PMID 40586870)pubmed.ncbi.nlm.nih.gov
- PubMedMarchand L et al. Diabet Med 2021 (PMID 32799379)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- A Third Way an Adverse Effect Can AriseSome effects follow not from the drug but from what the drug achieves. Any intervention producing the same change as fast would produce them too.
- Comparing Things That Were Never ComparedWhen no head-to-head exists, a network meta-analysis links treatments through shared comparators. It rests on an assumption worth understanding.
- A Second Entrant to Tirzepatide's MechanismVK2735 is a GIP/GLP-1 dual agonist - the same receptor pair as tirzepatide. Its Phase 2 VENTURE study ran 13 weeks, too short to compare with 72-week data.
- A GLP-1/Glucagon Dual Aimed at the LiverPemvidutide pairs GLP-1 with glucagon receptor agonism and was studied for 24 weeks in metabolic dysfunction-associated steatotic liver disease.
- An Amylin Analogue Built to Stand AlonePetrelintide is described as a potent, stable, long-acting human amylin analogue - engineered by Zealand Pharma with Boehringer Ingelheim.